Cited 32 times in
The prognostic significance of postoperative neutrophil-to-lymphocyte ratio after radical prostatectomy for localized prostate cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강동혁 | - |
dc.contributor.author | 강용진 | - |
dc.contributor.author | 김명수 | - |
dc.contributor.author | 윤철용 | - |
dc.contributor.author | 정원식 | - |
dc.contributor.author | 조강수 | - |
dc.contributor.author | 최영득 | - |
dc.contributor.author | 함원식 | - |
dc.date.accessioned | 2017-11-02T08:26:52Z | - |
dc.date.available | 2017-11-02T08:26:52Z | - |
dc.date.issued | 2017 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/154479 | - |
dc.description.abstract | BACKGROUND: The pretreatment neutrophil-to-lymphocyte ratio has prognostic value after radical prostatectomy for treating localized prostate cancer. However, the use of postoperative neutrophil-to-lymphocyte ratio has not been evaluated in this population. We investigated the prognostic significance of early postoperative neutrophil-to-lymphocyte ratio after radical prostatectomy for prostate cancer. METHODS: We retrospectively reviewed clinical data from 2,302 patients with localized prostate cancer who underwent radical prostatectomy at our institution between years 2000 and 2010. Only patients with pre- and postoperative complete blood counts with differential results were included. Patients who received neoadjuvant or postoperative adjuvant treatment and those without adequate medical records were excluded. Kaplan-Meier analyses were performed to analyze biochemical recurrence-free survival and overall survival rates. Univariate and multivariate Cox regression models were used for each endpoint. RESULTS: Kaplan-Meier curves showed that high postoperative neutrophil-to-lymphocyte ratio (>3.5) was significantly associated with decreased biochemical recurrence-free survival (p = 0.009) and overall survival (p = 0.010). In the univariate and multivariate Cox regression analyses, high postoperative neutrophil-to-lymphocyte ratio was a significant predictor of biochemical recurrence (hazard ratio 1.270, p = 0.008) and overall survival (hazard ratio 1.437, p = 0.033). CONCLUSIONS: Our results demonstrate that postoperative neutrophil-to-lymphocyte ratio is an independent factor for biochemical recurrence and overall survival in patients who underwent radical prostatectomy for prostate cancer. These findings suggest that neutrophil-to-lymphocyte ratio can be a potentially valuable tool for stratifying high-risk patients and facilitating choices of postoperative therapy in patients with prostate cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Impact Journals | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lymphocytes/pathology* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neutrophils/pathology* | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Prostatectomy/methods* | - |
dc.subject.MESH | Prostatic Neoplasms/blood* | - |
dc.subject.MESH | Prostatic Neoplasms/surgery* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.title | The prognostic significance of postoperative neutrophil-to-lymphocyte ratio after radical prostatectomy for localized prostate cancer | - |
dc.type | Article | - |
dc.publisher.location | United States | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Urology | - |
dc.contributor.googleauthor | Won Sik Jang | - |
dc.contributor.googleauthor | Kang Su Cho | - |
dc.contributor.googleauthor | Myung Soo Kim | - |
dc.contributor.googleauthor | Cheol Yong Yoon | - |
dc.contributor.googleauthor | Dong Hyuk Kang | - |
dc.contributor.googleauthor | Yong Jin Kang | - |
dc.contributor.googleauthor | Won Sik Jeong | - |
dc.contributor.googleauthor | Won Sik Ham | - |
dc.contributor.googleauthor | Young Deuk Choi | - |
dc.identifier.doi | 10.18632/oncotarget.14349 | - |
dc.contributor.localId | A04711 | - |
dc.contributor.localId | A05091 | - |
dc.contributor.localId | A04988 | - |
dc.contributor.localId | A05180 | - |
dc.contributor.localId | A03801 | - |
dc.contributor.localId | A04111 | - |
dc.contributor.localId | A04337 | - |
dc.contributor.localId | A04870 | - |
dc.contributor.localId | A05268 | - |
dc.relation.journalcode | J02421 | - |
dc.identifier.eissn | 1949-2553 | - |
dc.identifier.pmid | 28052031 | - |
dc.subject.keyword | biochemical recurrence | - |
dc.subject.keyword | neutrophil-to-lymphocyte ratio | - |
dc.subject.keyword | prostate cancer | - |
dc.subject.keyword | radical prostatectomy | - |
dc.subject.keyword | survival | - |
dc.contributor.alternativeName | Kang, Dong Hyuk | - |
dc.contributor.alternativeName | Kang, Yong Jin | - |
dc.contributor.alternativeName | Kim, Myung Soo | - |
dc.contributor.alternativeName | Yoon, Cheol Yong | - |
dc.contributor.alternativeName | Jeong, Won Sik | - |
dc.contributor.alternativeName | Cho, Kang Su | - |
dc.contributor.alternativeName | Choi, Young Deuk | - |
dc.contributor.alternativeName | Ham, Won Sik | - |
dc.contributor.affiliatedAuthor | Kang, Yong Jin | - |
dc.contributor.affiliatedAuthor | Kim, Myung Soo | - |
dc.contributor.affiliatedAuthor | Yoon, Cheol Yong | - |
dc.contributor.affiliatedAuthor | Jeong, Won Sik | - |
dc.contributor.affiliatedAuthor | Cho, Kang Su | - |
dc.contributor.affiliatedAuthor | Choi, Young Deuk | - |
dc.contributor.affiliatedAuthor | Ham, Won Sik | - |
dc.contributor.affiliatedAuthor | Kang, Dong Hyuk | - |
dc.citation.title | Oncotarget | - |
dc.citation.volume | 8 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 11778 | - |
dc.citation.endPage | 11787 | - |
dc.identifier.bibliographicCitation | ONCOTARGET , Vol.8(7) : 11778-11787, 2017 | - |
dc.date.modified | 2017-11-01 | - |
dc.identifier.rimsid | 43053 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.